Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

45

Revenue 2017

Zytiga

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer

At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.

J&J’s Erleada first US drug for non-metastatic prostate cancer

J&J’s Erleada first US drug for non-metastatic prostate cancer momentum before Zytiga (abiraterone acetate) - its current blockbuster medicine for CRPC - faces generic competition in the US, which accounted for around half of the drug’s $2.5bn in sales in

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... The market category will see some significant disruption later

EC expands Janssen’s prostate cancer drug reach

EC expands Janssen’s prostate cancer drug reach EC expands Janssen’ s prostate cancer drug reach. Zytiga plus predinson/prednisolone will now treat mHSPC patients. ... Janssen has chalked up a significant win in the European market following a ruling on its prostate cancer drug Zytiga (abiraterone

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics